Mylan Vice Chairman and CEO Robert J. Coury to Ring NASDAQ Stock Market Op...(e leading diversified generic and specia...),Health

Date:2/19/2009

e leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest -- and highest quality -- product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. For more information, please visit www.mylan.com.

'/>"/>

SOURCE Mylan Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine news :

1. Mylan Schedules Fourth Quarter Financial Results Conference Call and Live Webcast
2. Mylan Receives FDA Approval for First-to-File Generic Depakote(R) ER
3. Mylan Declares Quarterly Preferred Stock Dividend
4. Mylan Receives Final FDA Approvals for Generic Versions of Lamictal(R) Tablets and Lamictal(R) CD
5. Mylan Receives Final FDA Approval for Generic Version of Prilosec(R) Delayed-Release Capsules, 40 mg
6. U.S. Patent and Trademark Office Issues Mylans Specialty Division, Dey L.P., Three Additional Patents Protecting Perforomist(R) Inhalation Solution
7. Mylan to Present at the 27th Annual J.P. Morgan Healthcare Conference
8. Mylans Matrix Receives Final FDA Approval for the Generic Version of the Antiretroviral Zerit(R) Capsules
9. Mylan Announces Move to NASDAQ Stock Market
10. Mylan Announces Settlement Agreement with Novartis Related to Femara(R) First- to-File Opportunity
11. Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem(R) Pulvules(R) Capsules